NVO$50.26
$49.17
Chart
Performance
Key Stats
AI NVO Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyNovo Nordisk exhibits strong fundamental performance with robust growth and profitability. Thematic tailwinds in obesity and diabetes care are significant. Technical indicators suggest a recent positive shift, though some short-term signals indicate potential consolidation.
Thematic
Novo Nordisk is a leader in the growing pharmaceutical markets for diabetes and obesity care, with expanding applications into cardiovascular and rare diseases. The increasing global prevalence of these conditions provides substantial long-term growth potential.
Fundamental
Novo Nordisk demonstrates exceptional financial health with strong revenue and profit growth, impressive margins, and a solid balance sheet. Its valuation is premium but justified by its performance and market position.
Technical
The stock shows strength with multiple moving averages in bullish territory. However, some shorter-term oscillators are neutral or slightly bearish, suggesting a pause or minor correction before further upward movement.
| Factor | Score |
|---|---|
| Diabetes & Obesity Care Market Growth | 95 |
| Diversification into New Therapies | 80 |
| Innovation Pipeline Strength | 85 |
| Regulatory and Pricing Pressures | 65 |
| ESG Integration | 80 |
| Factor | Score |
|---|---|
| Valuation | 60 |
| Profitability | 95 |
| Growth | 90 |
| Balance Sheet Health | 85 |
| Cash Flow Generation | 90 |
| Earnings Stability & Growth | 85 |
| Factor | Score |
|---|---|
| Trend Analysis | 70 |
| Momentum Indicators | 60 |
| Volume | 75 |
| Short-term Oscillators | 50 |
| Support/Resistance Levels | 65 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Strong Earnings Beat
The latest reported EPS of $6.53 significantly exceeded the analyst estimate of $6.11, representing a positive surprise of 6.94%. This indicates robust profitability and operational efficiency.
Positive Short-Term Momentum
The stock has shown positive performance over multiple short-term periods, with a 5-day return of 8.95% and a 1-month return of 4.48%. This suggests current investor interest and buying pressure.
Bearish Points (7)
Significant Long-Term Decline
The stock has experienced a substantial decline over the past year (-43.08%) and year-to-date (-17.88%), indicating significant underlying challenges or a bearish sentiment among investors.
Overbought Signals on Shorter Timeframes
Several short-term technical indicators, such as RSI (54.88 on 1m, 59.0 on 5m), Stochastic %K (75.55 on 1m, 85.53 on 5m), and Commodity Channel Index (128.86 on 5m), suggest the stock might be approaching or in overbought territory, potentially leading to a short-term pullback.
Calendar
March 2025
31
Ex-Dividend Date
April 2025
8
Next Dividend Date
August 2025
6
Next Earnings Date
H: $6.09
A: $5.98
L: $5.92
H: 80.48B
A: 76.68B
L: 72.94B
Profile
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Seasonals
Price Target
86.96 USD
The 39 analysts offering 1 year price forecasts for NVO have a max estimate of 111.91 and a min estimate of 61.58.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 100
Direct and fierce competitor in GLP-1 receptor agonists for diabetes and obesity (e.g., Mounjaro, Zepbound), making it a primary benchmark for NVO's core growth drivers.
Weight: 95
Emerging direct competitor in the obesity and metabolic disease space with promising GLP-1/GIP dual agonist candidates, often seen as a potential acquirer target for larger pharma.
Weight: 90
Major pharmaceutical company actively developing oral GLP-1 candidates for obesity, positioning it as a significant potential competitor to NVO's market dominance.
Weight: 88
Large biotechnology company with a promising obesity drug (Maritide) in its pipeline, which could compete with NVO's Wegovy.